Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results

Vir Biotechnology, Inc. VIR reported worse-than-expected Q4 results.

Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s quarterly sales came in at $49.41 million, versus estimates of $97.30 million.

Vir Biotechnology shares gained 5.1% to $24.00 in pre-market trading.

These analysts made changes to their price targets on Vir Biotechnology following the release of results.

• JP Morgan cut the price target on Vir Biotechnology from $35 to $34. JP Morgan analyst Eric Joseph upgraded the stock from Neutral to Overweight.
• HC Wainwright & Co. slashed the price target on Vir Biotechnology from $125 to $100. HC Wainwright & Co. analyst Patrick Trucchio maintained a Buy rating.

Check This Out: Top 5 Materials Stocks That Could Lead To Your Biggest Gains In March